Skip to Content
Merck

SML0293

Telbivudine

≥98% (HPLC)

Synonym(s):

β-L-Thymidine, 1-(2-Deoxy-β-L-erythro-pentofuranosyl)-5-methyl-2,4(1H,3H)-Pyrimidinedione, 2′-Deoxy-L-thymidine, Epavudine, L-Thymidine, NV 02B, Sebivo

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C10H14N2O5
CAS Number:
3424-98-4
Molecular Weight:
242.23
NACRES:
NA.77
PubChem Substance ID:
329825300
UNSPSC Code:
12352200
MDL number:
MFCD02683612

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Telbivudine, ≥98% (HPLC)

InChI

1S/C10H14N2O5/c1-5-3-12(10(16)11-9(5)15)8-2-6(14)7(4-13)17-8/h3,6-8,13-14H,2,4H2,1H3,(H,11,15,16)/t6-,7+,8+/m1/s1

SMILES string

CC1=CN([C@@H]2C[C@@H](O)[C@H](CO)O2)C(=O)NC1=O

InChI key

IQFYYKKMVGJFEH-CSMHCCOUSA-N

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D -15 to -22°, c = 1 in H2O

color

white to beige

solubility

H2O: 10 mg/mL (clear solution)

storage temp.

2-8°C

Quality Level

100

Application

Telbivudine has been used to explore the mechanisms of telbivudine (LdT) induced creatine kinase (CK) elevation.

Biochem/physiol Actions

Telbivudine is a nucleoside analog that is widely used to treat hepatitis B virus (HBV) infection.
Telbivudine is a synthetic molecule containing β-L-configuration. Telbivudine improves the estimated glomerular filtration rate (eGFR) in response to chronic hepatitis B (CHB). It prevents perinatal transmission and enhances the hepatitis B e antigen (HBeAg) seroconversion. It is also known to cause side effects such as creatine kinase (CK) elevation and fatal rhabdomyolysis.
Telbivudineis a Hepatitis B antiviral agent.

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
036M4727V
082M4701V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Timothy P Wakeman et al.
Oncotarget, 8(48), 83975-83985 (2017-11-16)
Hexavalent chromium (Cr[VI]) is associated with occupational lung cancer and poses a significant public health concern. When exposed to Cr[VI], cells rapidly internalize this compound and metabolize it to Cr[III]. Byproducts of Cr[VI] metabolism include unstable Cr[V] and Cr[IV] intermediates
Faezeh Koohestani et al.
PloS one, 8(9), e75844-e75844 (2013-09-17)
Uterine leiomyomas (ULs) are benign tumors occurring in the majority of reproductive aged women. Despite the high prevalence of these tumors, little is known about their etiology. A hallmark of ULs is the excessive deposition of extracellular matrix (ECM), primarily
Xingfei Pan et al.
Scientific reports, 10(1), 13631-13631 (2020-08-14)
Few studies were conducted to assess safety and efficacy of continuous antiviral therapy administrated from preconception. In the present study, 136 eligible women with chronic HBV infection were recruited, and assigned to active chronic hepatitis B (CHB) (Group A, B
Zhaoping Yan et al.
Medicine, 97(31), e11716-e11716 (2018-08-05)
The aim of this study was to evaluate clinical efficacy of telbivudine in treatment of hepatitis B virus-associated glomerulonephritis (HBV-GN).A total of 43 HBV-GN patients combined with chronic hepatitis B were treated with telbivudine for 104 weeks. Serum levels of
Gang Huang et al.
Annals of surgery, 268(6), 943-954 (2018-03-10)
Despite antiviral treatment has been shown to reduce hepatocellular carcinoma (HCC) recurrence after curative treatment for hepatitis B virus (HBV)-related HCC in patients with high preoperative HBV-DNA levels, it is still unclear whether antiviral therapy is useful in reducing recurrence
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service